REFRACTORY CANCER

This adverse event was reported 214 times

REFRACTORY CANCER is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ETOPOSIDE PHOSPHATE 13 0.0080
1 L-TRYPTOPHAN 1 0.0023
2 CEDAZURIDINE AND DECITABINE 2 0.0020
3 AXICABTAGENE CILOLEUCEL 17 0.0017
4 POLATUZUMAB VEDOTIN 17 0.0017
5 ATRACURIUM BESYLATE 1 0.0014
6 CLOFARABINE 3 0.0013
7 ARSENIC TRIOXIDE 3 0.0013
8 DINUTUXIMAB 1 0.0012
9 BENDAMUSTINE HCL 17 0.0011
See all drugs enriched for association with REFRACTORY CANCER